The first domestic anti -new crown oral medicine was included in the new crown diagnosis and treatment plan

On August 9th, the General Office of the National Health and Health Commission and the Office of the State Administration of Traditional Chinese Medicine issued the "Notice on Treatment of Azf's Fixed Sets into the Diagnosis and treatment of new coronary virus pneumonia" (hereinafter referred to as the "Notice"), and pointed out that according to the national drug regulatory supervisor The bureau has the conditions to approve the approved opinion of the treatment of the new type of coronary virus pneumonia adaptation. In order to further improve the new type of coronary virus pneumonia antiviral treatment plan, after research, the medicine was included in the "new coronary virus pneumonia diagnosis and treatment plan ( Ninth Edition) ".

According to the "Notice", Azf's fixed tablet is used to treat adult patients with COV-ID-19). The amount of usage is swallowed by the entire space, 5mg each time, once a day, the course of treatment is not more than 14 days.

At the same time, the "Notice" also reminded that it is not recommended to use it during pregnancy and lactation, and patients with medium -weight liver and renal function injury should be used with caution. Patients should take medicine under the guidance of the doctor.

On July 25, the State Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the Drug Management Law in accordance with the relevant provisions of the Drug Management Law. Symptom registration application. This means that Azf's fixed film has become the first newly -developed oral small crown therapy drug in China. On August 2nd, Azf's fixed film has been officially put into production in Pingdingshan City, and the annual output of the future preparation can reach 3 billion pieces.

- END -